European Patent Office Allows Advaxis/U. Penn Modified LLO Patent

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University of Pennsylvania. It extends protection for Advaxis’ use of proprietary antigen-adjuvant fusion proteins beyond Listeria to viral and DNA vaccine vectors as well. This will provide patent protection to 2025.

The Listeria protein listeriolysin O (LLO) is the highly immunogenic primary virulence factor for Lm. Advaxis uses this natural immunity to LLO and similar proteins (PEST containing proteins) to enhance the response to tumor and infectious disease antigens by fusing a bioengineered form of LLO (or similar protein) that has been designed for this purpose to any selected antigen, thus creating an antigen-adjuvant molecule with greater immuno-reactivity than the antigen alone.

Although Advaxis typically delivers these fusion proteins by engineering live Listeria to make and secrete them from within a patient’s cells, the technology has found use in other research laboratories and has been inserted into a number of non-Listeria vaccine vectors. This patent provides Advaxis with proprietary intellectual property protection for the use of LLO and other PEST containing proteins when used in viral and DNA vaccine vectors.

Advaxis Proprietary Technology

Advaxis technology is based upon the ability of antigen-adjuvant fusion proteins to stimulate a therapeutic immune response against cancer and infectious disease; especially when synthesized and secreted by live Listeria monocytogenes (Lm). This recently approved patent will be the 28th patent in the Advaxis portfolio, with 44 additional applications pending. This intellectual property protection extends to 3 engineered strains of Lm that have been developed for use as human vaccine vectors. Additional vectors are currently in development. Additionally, the Advaxis portfolio consists of patents which protect compositions, methods of manufacture, and uses of various families of antigen-adjuvant fusion proteins made and secreted by live Listeria, or administered independent of Listeria. These include fusion proteins based upon LLO, ActA, and other PEST containing proteins. The number of proprietary Lm strains and fusion protein families enables Advaxis to construct a large number of different vaccines based upon the antigen(s) used and the disease to be treated.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir
Executive Director
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]
or
Diana Moore
Analyst
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]

KEYWORDS:   United States  Europe  North America  New Jersey  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.